Track MediciNova, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

MediciNova, Inc. MNOV · Stock Open MediciNova, Inc. in new tab

1.39 USD
EPS
-0.21
P/B
1.86
ROE
-25.56
Beta
0.71
Target Price
8.25 USD
Loading chart...
Key Metrics
Earnings dateFeb. 19, 2027
EPS-0.21
Book Value0.76
Price to Book1.86
Debt/Equity0.31
% Insiders2.864%
Growth
Revenue Growth2.41%
Estimates
Forward P/E-2.74
Forward EPS-0.52
Target Mean Price8.25

DCF valuation

Model fair value for MediciNova, Inc. (MNOV)
Result
Sign in to run the valuation for MNOV.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
4 analysts · consensus None · mean target 8.25 USD (low 6.00, high 11.00) · as of 11 Nov 2026
Low 6.00
Mean 8.25
High 11.00
Price 1.39
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

MediciNova, Inc. Logo MediciNova, Inc. Analysis (MNOV)

United States Health Care Official Website Stock

Is MediciNova, Inc. a good investment? MediciNova, Inc. (MNOV) is currently trading at 1.39 USD. Market analysts have a consensus price target of 8.25 USD. This suggests a potential upside from current levels.

Earnings Schedule: MediciNova, Inc. is expected to release its next earnings report on Feb. 19, 2027. The market consensus estimate for Forward EPS is -0.52.

Investor FAQ

Does MediciNova, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is MediciNova, Inc.?

MediciNova, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 19, 2027. The company currently has a trailing EPS of -0.21.

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

Exchange Ticker
NMS (United States) MNOV
JPX (Japan) 4875.T
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion